For each technology, innovators are invited to review a set of access principles that will reinforce access opportunities throughout a technology development, manufacturing, and distribution life cycle.
These access principles set the ground for reinforced collaboration for long-acting product candidates’ development, encourage sharing of technical data to achieve public health benefits and support the establishment of appropriate strategies for timely and affordable access in low and middle-income countries, including through licensing.
Innovators may show their commitment level by indicating their agreement to each of these principles. This commitment is shown as colour variations on their technology card in LAPaL indicating that the innovator agrees, does not agree, or agrees under certain conditions to the proposed access principles.
LAPaL is a non-exhaustive source of information on long-acting platform technologies in a disease-agnostic approach. When a platform technology is being developed in association with a therapeutic agent or agents, these are listed as potential applications.
Initially, LAPaL is focusing on long-acting technologies that have foreseen applications with potential impact for global health. The scope is therefore wide, although initially prioritising technologies with applications to relieve health conditions in line with MPP and Unitaid historic mandates: HIV, tuberculosis, hepatitis and malaria prevention and treatment. A particular attention is given to multi-purpose technologies targeting for example HIV and another viral infection or HIV and pregnancy. Potential applications to other APIs and other health areas are also listed.
In its next iteration, LAPaL will encompass not only long-acting platforms, but also candidate long-acting agents. This expansion will be conducted in collaboration with LEAP, with support from Unitaid.
As a long-acting technology developer, you can submit your technology to LAPaL, or we will reach out to you to fact-check your technology profile that we would have put together using publicly available information. You will have the opportunity to provide information about the technology properties, development stage, potential applications and the most relevant patents and licences.
If you are curious about long-acting technologies, LAPaL might be a go-to resource for you, whether you are a tech innovator or not. All LAPaL users are welcome to contribute to this collaborative tool. We will be happy to hear your thoughts and discuss your proposals to help us improve the database content, looks and features.
A long-acting technology with potential public health benefit might end up in LAPaL either through direct submission by the innovator or through MPP curation and reach out to innovator for support in submission. In both cases, we envisage a close collaboration with the innovator to ensure they are associated to all relevant updates to their technologies.
In some cases, we may identify a particularly important technology from a public health perspective, but we may face challenges in involving the innovators in the data collection and updating process. If this occurs, we will upload the technology profile and flag it as “MPP-sourced” until the innovator fact-checks it.
If you would like to submit your long-acting technology to LAPaL, you will need to create a user account that will be associated with that technology. You will then be guided through a twenty questions online form to provide information related to:
To start the submission process and creating a technology card, click on “submit a technology” tab and create an account or use an existing account. If you need to reset your password, please check the spam folder in case the verification email is delayed.
LAPaL is coordinated by the Medicines Patent Pool (MPP), a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Funding for this database as well as for MPP’s work in the long-acting space is secured through a Unitaid grant.
MPP would like to acknowledge the technical support from:
Furthermore, we are grateful to all the innovators and stakeholders who have provided data and advice to enrich the repository and who are putting in their best efforts to advance the long-acting technologies pipeline with access considerations as an integral part of the work. The platform was built by MobileThinking in Geneva.
Every technology has its own “technology card” with the name of the technology and its main developer, as well as an illustration. The “Summary” button allows for a shortcut to an overview of the technology main features as well as to the Access Principles commitment from the innovator.
For a more detailed view, the “see more” button will take the user to a dedicated page with various tabs related to the technology. These tabs cover:
LAPaL provides a non-exhaustive list of patents related to the technology and potential application products when the latter are available in MedsPaL. The information about these patents and licences are shown in LAPaL as a summary table indicating whether patents relate to the technology or to its potential applications.
For each patent family, an abstract is provided, and the country patent applications are listed. LAPaL patent descriptions may be reformulated by MPP and may not be the official descriptions appearing in patent documents.
LAPaL builds on MPP’s experience in mapping patents on key health technologies through MedsPaL. MedsPaL is MPP’s patents and licences database for medicines. It provides information on the patent and licensing status of patented essential medicines in low- and middle-income countries.
LAPaL administrators use the information provided by the innovators on the most relevant patents and licences related to their technology (one representative publication per family). This information is used to map equivalent patents and patent applications worldwide as well as their latest status.
When a technology is “MPP sourced”, the search for relevant patents will be performed in-house.
When potential applications with APIs are listed by the innovators, a second list is created with the most relevant patents and licences related to this API.
Moreover, when a licence agreement related to the technology or the potential APIs to be potentially used with it has been signed, this is highlighted and a link to the licence is provided.
If the API is already included in MedsPaL, the patent data for this API will be retrieved from MedsPaL.
An important difference with the patent and licensing information provided in MedsPaL, is that it not only includes information for low and middle-income countries as defined by the World Bank, for which patent data could be obtained, but also high-level information on high-income countries status.
LAPaL can be browsed by clicking on a given “technology card”.
If you are looking for a specific technology or product, you can use the LAPaL search engine by technology name by developer/innovator or by potential matching APIs (Active Pharmaceutical Ingredients).
Another possibility is to select various options in the drop-down menus of the technology characteristics on the left bar.
In March 2022, a new search filter was added for APIs search. The categorisation of APIs is based on WHO Collaborating Centre for Drug Statistics Methodology. Therefore, some APIs appear more than one time (as part of more than one family of agents).
For a more comfortable user experience, a keywords pool tab is shown at the top of the screen, with all ticked search words, to fine-tune search criteria.
We will be happy to receive suggestions and enquiries related to LAPaL or the long-acting project more generally. Please use the contact form on the top bar or write to
LA PaL has a news section that is regularly aggregated into a newsletter. If you are interested to receive LAPaL updates, please subscribe to the newsletter through the “news” tab. Unfortunately, the newsletter sometimes lands in the spam folder, so please also check that one from time to time or whitelist the “@medicinespatentpool.org” domain.
MPP will use the information you provide by subscribing to be in touch with you and to provide updates. We will treat your information with respect. You can change your mind and unsubscribe at any time by clicking the unsubscribe link in the footer of any newsletter, or by contacting us.
We use Mailchimp as our marketing platform. By subscribing, you agree that we may process your information in accordance with the above terms and you acknowledge that your information will be transferred to Mailchimp for processing.
Users should NOT consider LAPaL a complete and authoritative source of information. The patents landscape for each technology is not intended as a ‘freedom-to-operate’ analysis. LAPaL only provides a snapshot at a point in time, based on the information available to MPP. The technical information provided is based on publicly available information, should not be considered as exhaustive and may have lapsed.
All MedsPaL disclaimers apply to LAPaL patent information. In particular, we do not accept any legal responsibility for the accuracy of data. We do not guarantee it is complete, up to date or fit for specific purposes. Users should undertake additional country searches and legal analysis before making any procurement or business decision based on the patent landscape.
A full understanding of the patent situation in any country, for a specific technology or agent, requires additional information and analysis not provided in LAPaL. This includes an analysis of the specific claims of a national/regional patent application or granted patent. Users should also consider whether the country is a Least Developed Country (LDC) and may benefit from the transition period provided by the World Trade Organization TRIPS Agreement, or whether the country is making use of any of the other flexibilities available under national or international regulations.
We would like to acknowledge the support and technical assistance from the following organizations and groups:
We would also like to thank the innovators who have kindly contributed to the database and to the users providing their valuable feedback.
We have listed a group of resources that could be of interest if you are into long-acting.
If you think another resource should be listed below, please let us know!
Thanks for your collaboration.
Scientific publications and reviews, reports, infographics, blog posts, interviews, etc. We love reading the latest news and publications from the long-acting world.
Please send us your citation so we can add it to the reading roll.
LAPaL was launched in May 2021 and counts, as of December 2021, 4 long-acting platform technologies with many potential applications in the fields of HIV prevention and treatment, hepatitis B treatment, malaria treatment, type 2 diabetes and metabolic disorders management, pain management and contraception, among other applications.
One of these technologies was recently licensed to the MPP for a potential use in the field of treatment of HIV.